Immune selection in vitro reveals human immunodeficiency virus type 1 nef sequence motifs important for its immune evasion function in vivo

Journal of Virology

Volumn 86, Issue 13, 2012, Pages 7126-7135

  Lewis, Martha J ^a   Lee, Patricia ^a   Ng, Hwee L ^a   Yang, Otto O ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN;

ADAPTIVE IMMUNITY; AMINO ACID SEQUENCE; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DIVERSIFYING SELECTION; DOWN REGULATION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOLECULAR EVOLUTION; MOLECULAR MODEL; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; NEF GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN POLYMORPHISM; PURIFYING SELECTION; SEQUENCE ANALYSIS; SITE DIRECTED MUTAGENESIS; T CELL DEPLETION; VIRUS GENE; VIRUS ISOLATION;

AMINO ACID SUBSTITUTION; DOWN-REGULATION; EVOLUTION, MOLECULAR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV INFECTIONS; HIV-1; HUMANS; IMMUNE EVASION; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; RNA, VIRAL; SELECTION, GENETIC; SEQUENCE ANALYSIS, DNA; T-LYMPHOCYTES, CYTOTOXIC; VIRULENCE FACTORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864133984     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00878-12     Document Type: Article

References (69)

1. Adnan S, et al. 2006. Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood 108:3414 -3419.
2. Ahmad N, Venkatesan S. 1988. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 241:1481-1485.
3. Akari H, et al. 2000. Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation. J. Virol. 74:2907-2912.
4. Ali A, Jamieson BD, Yang OO. 2003. Half-genome human immunodeficiency virus type 1 constructs for rapid production of reporter viruses. J. Virol. Methods 110:137-142.
5. Ali A, Ng HL, Dagarag MD, Yang OO. 2005. Evasion of cytotoxic T lymphocytes is a functional constraint maintaining HIV-1 Nef expression. Eur. J. Immunol. 35:3221-3228.
6. Ali A, et al. 2003. Broadly increased sensitivity to cytotoxic T lymphocytes resulting from Nef epitope escape mutations. J. Immunol. 171:3999- 4005.
7. Arold S, et al. 2000. Characterization and molecular basis of the oligomeric structure of HIV-1 nef protein. Protein Sci. 9:1137-1148.
8. Baur AS, et al. 1994. HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization. Immunity 1:373-384.
9. Bodéus M, Marie-Cardine A, Bougeret C, Ramos-Morales F, Benarous R. 1995. In vitro binding and phosphorylation of human immunodeficiency virus type 1 Nef protein by serine/threonine protein kinase. J. Gen. Virol. 76:1337-1344.
10. Brumme ZL, et al. 2009. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One 4:e6687. doi: 10.1371/journal.pone.0006687.
11. Carl S, et al. 2001. Modulation of different human immunodeficiency virus type 1 Nef functions during progression to AIDS. J. Virol. 75:3657- 3665.
12. Cohen GB, et al. 1999. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 10:661- 671.
13. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. 1998. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391:397- 401.
14. Couillin I, et al. 1994. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J. Exp. Med. 180:1129 -1134.
15. Craig HM, Pandori MW, Guatelli JC. 1998. Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc. Natl. Acad. Sci. U. S. A. 95:11229 -11234.
16. Crooks GE, Hon G, Chandonia JM, Brenner SE. 2004. WebLogo: a sequence logo generator. Genome Res. 14:1188 -1190.
17. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258:1938 -1941.
18. Deacon NJ, et al. 1995. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270: 988-991.
19. Dyer WB, et al. 1997. Lymphoproliferative immune function in the Sydney Blood Bank Cohort, infected with natural nef/long terminal repeat mutants, and in other long-term survivors of transfusion-acquired HIV-1 infection. AIDS 11:1565-1574.
20. Erdtmann L, et al. 2000. Two independent regions of HIV-1 Nef are required for connection with the endocytic pathway through binding to the mu 1 chain of AP1 complex. Traffic 1:871- 883.
21. Fackler OT, Baur AS. 2002. Live and let die: Nef functions beyond HIV replication. Immunity 16:493- 497.
22. Felsenstein J. 1989. PHYLIP-phylogeny inference package (version 3.2). Cladistics 5:164 -166.
23. Franken P, et al. 1997. HIV-1 Nef protein: purification, crystallizations, and preliminary X-ray diffraction studies. Protein Sci. 6:2681-2683.
24. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 350:508 -511.
25. Geffin R, et al. 2000. Functional and structural defects in HIV type 1 nef genes derived from pediatric long-term survivors. AIDS Res. Hum. Retroviruses 16:1855-1868.
26. Geyer M, Fackler OT, Peterlin BM. 2001. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2:580 -585.
27. Geyer M, Munte CE, Schorr J, Kellner R, Kalbitzer HR. 1999. Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein. J. Mol. Biol. 289:123-138.
28. Geyer M, et al. 2002. Subunit H of the V-ATPase binds to the medium chain of adaptor protein complex 2 and connects Nef to the endocytic machinery. J. Biol. Chem. 277:28521-28529.
29. Gibbs JS, Regier DA, Desrosiers RC. 1994. Construction and in vitro properties of HIV-1 mutants with deletions in " nonessential" genes. AIDS Res. Hum. Retroviruses 10:343-350.
30. Hodge DR, et al. 1998. Binding of c-Raf1 kinase to a conserved acidic sequence within the carboxyl-terminal region of the HIV-1 Nef protein. J. Biol. Chem. 273:15727-15733.
31. Huang Y, Zhang L, Ho DD. 1995. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J. Virol. 69:93-100.
32. Kestler HW, III, et al. 1991. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65:651- 662.
33. Kirchhoff F, et al. 1999. Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J. Virol. 73:5497-5508.
34. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228 -232.
35. Koenig S, et al. 1995. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:330 -336.
36. Krebs FC, Hogan TH, Quiterio S, Gartner S, Wigdahl B. 2001. Lentiviral LTR-directed expression, sequence variation, and disease pathogenesis. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM. http://www.hiv.lanl.gov/content/sequence/HIV/COMPENDIUM/2001/partI/Wigdahl.pdf.
37. Lama J, Mangasarian A, Trono D. 1999. Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr. Biol. 9:622- 631.
38. Lee CH, Saksela K, Mirza UA, Chait BT, Kuriyan J. 1996. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 85:931-942.
39. Lemey P, Rambaut A, Pybus OG. 2006. HIV evolutionary dynamics within and among hosts. AIDS Rev. 8:125-140.
40. Lewis MJ, et al. 2008. Functional adaptation of Nef to the immune milieu of HIV-1 infection in vivo. J. Immunol. 180:4075- 4081.
41. Liu LX, et al. 2000. Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions. J. Virol. 74:5310 -5319.
42. Lu X, Yu H, Liu SH, Brodsky FM, Peterlin BM. 1998. Interactions between HIV1 Nef and vacuolar ATPase facilitate the internalization of CD4. Immunity 8:647- 656.
43. Mangasarian A, Piguet V, Wang JK, Chen YL, Trono D. 1999. Nefinduced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking. J. Virol. 73:1964 -1973.
44. Mariani R, et al. 1996. High frequency of defective nef alleles in a longterm survivor with nonprogressive human immunodeficiency virus type 1 infection. J. Virol. 70:7752-7764.
45. Niederman TM, Thielan BJ, Ratner L. 1989. Human immunodeficiency virus type 1 negative factor is a transcriptional silencer. Proc. Natl. Acad. Sci. U. S. A. 86:1128 -1132.
46. Noviello CM, et al. 2007. Maintenance of Nef-mediated modulation of major histocompatibility complex class I and CD4 after sexual transmission of human immunodeficiency virus type 1. J. Virol. 81:4776-4786.
47. Piguet V, Trono D. 1999. A structure-function analysis of the nef protein of primate lentiviruses,p448-459. In Kuiken CL, et al (ed),Humanretroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, NM.
48. Piguet V, Trono D. 1999. The Nef protein of primate lentiviruses. Rev. Med. Virol. 9:111-120.
49. Piguet V, et al. 2000. HIV-1 Nef protein binds to the cellular protein PACS-1 to downregulate class I major histocompatibility complexes. Nat. Cell Biol. 2:163-167.
50. Pond SL, Frost SD, Muse SV. 2005. HyPhy: hypothesis testing using phylogenies. Bioinformatics 21:676-679.
51. Poon AF, et al. 2010. Phylogenetic analysis of population-based and deep sequencing data to identify coevolving sites in the nef gene of HIV-1. Mol. Biol. Evol. 27:819-832.
52. Posada D, Crandall KA. 1998. MODELTEST: testing the model of DNA substitution. Bioinformatics 14:817- 818.
53. Richter SN, Frasson I, Palu G. 2009. Strategies for inhibiting function of HIV-1 accessory proteins: a necessary route to AIDS therapy? Curr. Med. Chem. 16:267-286.
54. Riggs NL, Craig HM, Pandori MW, Guatelli JC. 1999. The dileucinebased sorting motif in HIV-1 Nef is not required for down-regulation of class I MHC. Virology 258:203-207.
55. Saksela K. 2004. Therapeutic targeting of interactions between Nef and host cell proteins. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4:315-319.
56. Saksela K, Cheng G, Baltimore D. 1995. Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef_ viruses but not for down-regulation of CD4. EMBO J. 14:484-491.
57. Salter RD, Howell DN, Cresswell P. 1985. Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. Immunogenetics 21:235- 246.
58. Sawai ET, et al. 1994. Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 91:1539 -1543.
59. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. 2008. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog. 4:e1000131. doi: 10.1371/journal.ppat.1000131.
60. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. 1996. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2:338 -342.
61. Smith BL, Krushelnycky BW, Mochly-Rosen D, Berg P. 1996. The HIV nef protein associates with protein kinase C theta. J. Biol. Chem. 271: 16753-16757.
62. Swigut T, et al. 2004. Impact of Nef-mediated downregulation of major histocompatibility complex class I on immune response to simian immunodeficiency virus. J. Virol. 78:13335-13344.
63. Tomiyama H, Akari H, Adachi A, Takiguchi M. 2002. Different effects of Nef-mediated HLA class I down-regulation on human immunodeficiency virus type 1-specific CD8(+) T-cell cytolytic activity and cytokine production. J. Virol. 76:7535-7543.
64. Ueno T, et al. 2008. CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J. Immunol. 180:1107- 1116.
65. Walker PR, et al. 2007. Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res. Hum. Retroviruses 23:204 -215.
66. Wick WD, Gilbert PB, Yang OO. 2009. Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. J. Virol. 83:2349- 2356.
67. Williams M, Roeth JF, Kasper MR, Filzen TM, Collins KL. 2005. Human immunodeficiency virus type 1 Nef domains required for disruption of major histocompatibility complex class I trafficking are also necessary for coprecipitation of Nef with HLA-A2. J. Virol. 79:632- 636.
68. Yang OO, et al. 2002. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol. 76:1626-1631.
69. Yang OO, et al. 2003. Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes. J. Exp. Med. 197:1365-1375.